Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 1/2014

Open Access 01-12-2014 | Short report

Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy

Authors: Boris Perelman, Areej Adil, Peter Vadas

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2014

Login to get access

Abstract

Background

Platelet-activating factor (PAF) is a highly potent phospholipid mediator responsible for the life-threatening manifestations of anaphylaxis. PAF acetylhydrolase (PAF-AH) inactivates PAF and protects against severe anaphylaxis whereas deficiency of PAF-AH predisposes to severe or fatal anaphylaxis. Determinants of PAF-AH activity have not been studied in patients with peanut allergy.

Objectives

To determine whether plasma PAF-AH activity in patients with peanut allergy is related to formation of circulating complexes with apolipoprotein B (apoB) the main surface protein on low density lipoprotein particles.

Methods

Plasma PAF-AH activity and apoB concentrations were measured in 63 peanut allergic patients (35 boys, 28 girls, ages 2 – 19 years). ApoB concentration was measured immunoturbidimetrically using goat anti-human apoB. The correlation between PAF-AH activity and apoB concentration was determined.

Results

A positive correlation was found between PAF-AH activity and apoB concentration (r2 = 0.59, P < 0.0001).

Conclusion

In peanut allergic patients, PAF-AH activity strongly correlates with apoB concentration, suggesting the presence of circulating PAF-AH- lipoprotein complexes.
Appendix
Available only for authorised users
Literature
1.
Yost CC, Weyrich AS, Zimmerman GA: The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie. 2010, 92 (6): 692-697. 10.1016/j.biochi.2010.02.011.PubMedCentralCrossRefPubMed
2.
Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M: Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms. J Clin Invest. 1988, 82: 1983-1991. 10.1172/JCI113818.PubMedCentralCrossRefPubMed
3.
Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA: Platelet-activating factor: a mediator for clinicians. J Intern Med. 1995, 238: 5-20. 10.1111/j.1365-2796.1995.tb00894.x.CrossRefPubMed
4.
Arias K, Baig M, Colangelo M, Chu D, Walker T, Goncharova S, Coyle A, Vadas P, Waserman S, Jordana M: Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut induced anaphylactic reactions. J Allergy Clin Immunol. 2009, 124: 307-314. 10.1016/j.jaci.2009.03.012.CrossRefPubMed
5.
Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, Cao WH, Kume K, Fukuchi Y, Ikuta K, Miyazaki J, Kumada M, Shimizu T: Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med. 1998, 187: 1779-1788. 10.1084/jem.187.11.1779.PubMedCentralCrossRefPubMed
6.
Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J: Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med. 2008, 358: 28-35. 10.1056/NEJMoa070030.CrossRefPubMed
7.
Vadas P, Perelman B, Liss G: Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol. 2013, 131: 144-149. 10.1016/j.jaci.2012.08.016.CrossRefPubMed
8.
Vadas P, Perelman B: Effect of epinephrine on platelet-activating-factor-stimulated human vascular smooth muscle cells. J Allergy Clin Immunol. 2012, 129: 1329-1333. 10.1016/j.jaci.2012.02.027.CrossRefPubMed
9.
Yanoshita R, Kudo I, Ikizawa K, Chang HW, Kobayashi S, Ohno M, Nojima S, Inoue K: Hydrolysis of platelet activating factor and its methylated analogs by acetylhydrolases. J Biochem. 1988, 103: 815-819.PubMed
10.
Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM: Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci. 1989, 86: 2393-2397. 10.1073/pnas.86.7.2393.PubMedCentralCrossRefPubMed
11.
Karasawa K, Harada A, Satoh N, Inoue K, Setaka M: Review: plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res. 2003, 42: 93-114. 10.1016/S0163-7827(02)00049-8.CrossRefPubMed
12.
Stafforini DM, McIntyre TM, M Carter E, Prescott SM: Human plasma platelet-activating factor acetylhydrolase association with lipoprotein particles and role in the degradation of platelet activating factor. J Biol Chem. 1987, 262: 4215-4222.PubMed
13.
Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000, 150: 413-419. 10.1016/S0021-9150(99)00406-2.CrossRefPubMed
14.
Zhang B, Fan P, Shimoji E, Itabe H, Miura S, Uehara Y, Matsunaga A, Saku K: Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis. 2006, 186: 291-301. 10.1016/j.atherosclerosis.2005.07.029.CrossRefPubMed
15.
Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem. 1999, 274: 7018-7024. 10.1074/jbc.274.11.7018.CrossRefPubMed
16.
Fielding PE, Fielding CJ: Dynamics of lipoprotein transport in the human circulatory system. Biochemistry of Lipids, Lipoproteins and Membranes. Edited by: Vance DE, Vance JE. 2002, Amsterdam: Elsevier, 527-552. 4CrossRef
17.
Vadas P, Liss G: Anaphylaxis: clinical patterns, mediator release and severity. J Allergy Clin Immunol. 2013
18.
Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, Coulson A, Hartnett L, Nagree Y, Cotterell C, Isbister GK: Anaphylaxis: Clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013, 132 (5): 1141-1149. 10.1016/j.jaci.2013.06.015.CrossRefPubMed
19.
Gardner AA, Reichert EC, Topham MK, Stafforini DM: Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein. J Biol Chem. 2008, 283: 17099-17106. 10.1074/jbc.M802394200.PubMedCentralCrossRefPubMed
20.
Triggiani M, Granata F, Giannattasio G, Marone G: Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol. 2005, 116: 1000-1006. 10.1016/j.jaci.2005.08.011.CrossRefPubMed
21.
Vadas P, Browning J, Edelson J, Pruzanski W: Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat. 1993, 8: 1-30.PubMed
22.
Guerra R, Zhao B, Mooser V, Stafforini DM, Johnston JM, Cohen JC: Determinants of plasma platelet activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res. 1997, 38: 2281-2288.PubMed
23.
Eisaf M, Tselepis AD: Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol. 2003, 66: 2069-2073. 10.1016/S0006-2952(03)00559-8.CrossRefPubMed
Metadata
Title
Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy
Authors
Boris Perelman
Areej Adil
Peter Vadas
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2014
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/1710-1492-10-20

Other articles of this Issue 1/2014

Allergy, Asthma & Clinical Immunology 1/2014 Go to the issue

Research

Identification of the main allergen sensitizers in an Iran asthmatic population by molecular diagnosis

Research

Reasons for prescribing second generation antihistamines to treat allergic rhinitis in real-life conditions and patient response

Case report

Successful use of daily intravenous infusion of C1 esterase inhibitor concentrate in the treatment of a hereditary angioedema patient with ascites, hypovolemic shock, sepsis, renal and respiratory failure

Short report

Maternal immunization with ovalbumin or Dermatophagoides pteronyssinus has opposing effects on FcγRIIb expression on offspring B cells

Research

Enhancement of OVA-induced murine lung eosinophilia by co-exposure to contamination levels of LPS in Asian sand dust and heated dust

Research

Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study